AstraZeneca PLC
AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca Core adjustment by Quarter
Core adjustment — Intangible asset amortisation & impairments ($M) ($M)
AstraZeneca Core adjustment: -$1,546M in Q2 2026, up 47.7% from a year earlier.
Latest, Q2 2026
-1,546
Period ended Jun 30, 2026
Change on a year earlier
+47.7%
-1,047 in Q2 2025
History
22 quarters
Since Q4 2020
Sources
22
Documents cited below
Where the Q2 2026 figure comes from
“|| Operating profit | | 3,164 | | | 100 | | | 1,546 | | 348 | | 5,158 | 12 | 10”
Source: Form 6-K FY2026Q2 Earnings Release ↗
Reported in Form 6-K / 20-F Reported-to-Core Reconciliation.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). AstraZeneca Core adjustment ($M), quarterly Q4 2020–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/adj-intang-amort-impair
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.